CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Vanda Pharmaceuticals Inc. v. Lupin Limited

1:15-cv-01073

Overview

Case Number 1:15-cv-01073
Filing Date 2015-11-19
Status Terminated
Termination Date 2020-07-15
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Lupin Pharmaceuticals Inc. Operating Company

Represented By

3 Attorneys Listed

James S. Green , Jr.

Seitz, Van Ogtrop & Green, P.A.

Tel: +1 (302) 888-0600

Seitz, Van Ogtrop & Green, P.A., 222 Delaware Avenue, Suite 1500

Jennifer L. Cree

Landis Rath & Cobb LLP

Tel: +1 (302) 467-4437
Fax: +1 (302) 467-4450

919 Market Street, Suite 1800, P.O. Box 2087

Daniel Bartley Rath

Landis Rath & Cobb LLP

Tel: +1 (302) 467-4400

919 Market Street, Suite 1800, P.O. Box 2087

Lupin Limited NPE (University / Research)

Represented By

6 Attorneys Listed

James S. Green , Jr.

Seitz, Van Ogtrop & Green, P.A.

Tel: +1 (302) 888-0600

Seitz, Van Ogtrop & Green, P.A., 222 Delaware Avenue, Suite 1500

Jennifer L. Cree

Landis Rath & Cobb LLP

Tel: +1 (302) 467-4437
Fax: +1 (302) 467-4450

919 Market Street, Suite 1800, P.O. Box 2087

Imron T. Aly

Email: ialy@schiffhardin.com

Helen H. Ji

Email: jelen.ji@afslaw.com

George Chih-Lun Yu

UNDELIVERABLE EMAIL 1/24/2020

Daniel Bartley Rath

Landis Rath & Cobb LLP

Tel: +1 (302) 467-4400

919 Market Street, Suite 1800, P.O. Box 2087

Plaintiff

Vanda Pharmaceuticals Inc. Operating Company

Represented By

9 Attorneys Listed

Nicholas Groombridge

Email: ngroombridge@paulweiss.com

Kira A. Davis

Email: kdavis@durietangri.com

Karen Jacobs

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Josephine Young

Email: jyoung@paulweiss.com

Ethan Haller Townsend

McDermott Will & Emery LLP

Tel: +1 (302) 484-3911

4th floor, 1007 North Orange Street, 4th Floor

Eric A. Stone

Email: estone@paulweiss.com

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Daniel J. Klein

Email: daklein@paulweiss.com

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts Counterparts in force
🏛️
USPTO PTAB Trials Counterparts in force
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

9 Patents

There are 9 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8586610
Methods for the administration of iloperidone
Filed: 2005-09-30
Issued: 2013-11-19
Active (1.0 yrs remaining) +763d PTA
Expires: 2027-11-02
US9138432
Methods for the administration of iloperidone
Filed: 2014-01-08
Issued: 2015-09-22
Active (7.1 yrs remaining)
Expires: 2034-01-08
US8652776
Prediction of QT prolongation based on SNP genotype
Filed: 2008-09-10
Issued: 2014-02-18
Active (3.8 yrs remaining) +720d PTA
Expires: 2030-08-31
US8999638
Method of treatment based on polymorphisms of the KCNQ1 gene
Filed: 2010-04-05
Issued: 2015-04-07
Active (3.9 yrs remaining) +206d PTA
Expires: 2030-10-28
US9072742
Method of predicting a predisposition to QT prolongation
Filed: 2010-04-05
Issued: 2015-07-07
Active (4.2 yrs remaining) +286d PTA
Expires: 2031-01-16

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Active Threat

Active Threat — Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+763 days) / Cellect Scrutiny — Over 763 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

17

Dispositive

6

Granted

0

Denied

0

Pending / Review

17

Motions by Category

Procedural / Extension Motion 11 Motion to Dismiss 6

Key Dispositive Motions & Rulings

Motion to Dismiss Pending / Under Review
Letter to The Honorable Gregory M. Sleet from James S. Green Jr. regarding Joint Agenda Letter for Discovery Teleconference for Monday, June 13, 2016 at 2:00 p....
Entry #38 • 2016-06-08 Document →
Motion to Dismiss Pending / Under Review
REPLY BRIEF re 20 MOTION to Dismiss Lupin Limited's Counterclaims No. 5-18 filed by Vanda Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1)(Townsend, Ethan) (E...
Entry #24 • 2016-03-10 Document →
Motion to Dismiss Pending / Under Review
STIPULATION TO EXTEND TIME to file a reply brief in support of Motion to Dismiss Lupin Limited's Counterclaims No. 5-18 (D.I. 20) to March 10, 2016 - filed by V...
Entry #23 • 2016-02-25 Document →
Motion to Dismiss Pending / Under Review
ANSWERING BRIEF in Opposition re 20 MOTION to Dismiss Lupin Limited's Counterclaims No. 5-18 filed by Lupin Limited, Lupin Pharmaceuticals Inc..Reply Brief due ...
Entry #22 • 2016-02-22 Document →
Motion to Dismiss Pending / Under Review
MOTION to Dismiss Lupin Limited's Counterclaims No. 5-18 - filed by Vanda Pharmaceuticals Inc. (Townsend, Ethan) Modified on 2/5/2016 (mdb). (Entered: 02/03/201...
Entry #20 • 2016-02-03 Document →
Motion to Dismiss Pending / Under Review
OPENING BRIEF in Support re 20 Motion to Dismiss Lupin Limited's Counterclaims No. 5-18 filed by Vanda Pharmaceuticals Inc..Answering Brief/Response due date pe...
Entry #21 • 2016-02-03 Document →

Docket Entries

(120 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Lupin Limited, Lupin Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1830648.) - filed by Vanda Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(dmp, ) (Entered: 11/20/2015)

Entry #1 • 2015-11-19
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (dmp, ) (Entered: 11/20/2015)

Entry #2 • 2015-11-19
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 10/09/2015. Date of Expiration of Patent: SEE ATTACHED FORM.Thirty Month Stay Deadline: 4/9/2018. (dmp, ) (Entered: 11/20/2015)

Entry #3 • 2015-11-19
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,586,610; 9,138,432;. (dmp, ) (Entered: 11/20/2015)

Entry #4 • 2015-11-19
1

Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Vanda Pharmaceuticals Inc.. (dmp, ) (Entered: 11/20/2015)

Entry #5 • 2015-11-19
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc